AI assistant
MACH7 TECHNOLOGIES LIMITED — Board/Management Information 2016
Jun 14, 2016
65285_rns_2016-06-14_7c33b0c3-98f7-4adc-9f70-a9943e6bd499.pdf
Board/Management Information
Open in viewerOpens in your device viewer
ASX Announcement
15 June 2016
==> picture [610 x 89] intentionally omitted <==
Director Appointment and Resignation
Melbourne, Australia; 15 June 2016: Mach7 Technologies Limited ( Mach7 or the Company ) (ASX: M7T ) is pleased to advise that Mr Alister Wayne Spittle has been appointed as a NonExecutive Director of Mach7, effective today 15 June 2016.
Mr Spittle has served as Executive Vice President of Samsung Medison & Samsung Health and Medical Equipment since 2013, and was involved with the strategic planning for Samsung’s entry into the healthcare arena three years ago. In his role with Samsung, Mr Spittle is responsible for product development and product portfolio planning, as well as developing sales and marketing strategies.
Prior to his role with Samsung, Mr Spittle enjoyed a career spanning 7 years with Philips Healthcare Asia Pacific, where he held roles including Senior Vice President and Chief Executive Officer, and was responsible for driving sales in both mature and growth markets in Asia Pacific. Mr Spittle has also held positions with the Health Department Victoria, ATL Ultrasound, Philips Medical Systems Australasia and Royal Philips Electronics.
Mr Spittle commented “I am pleased to join the Board of Mach7 Technologies. It is an exciting time where a company like Mach7 addresses the concerns of an ever changing landscape in the Healthcare IT space. We will not only drive change but deliver new and exciting products into the marketplace.”
The Company also advises that Mr Ken Poutakidis, Non-Executive Chairman, has retired from the Board, and Mr Damien Lim, Non-Executive Director, has been appointed as Chairman of the Board, effective today 15 June 2016.
Mr Damien Lim, Non-Executive Chairman of Mach7, commented “We are delighted that Wayne will be joining the Board and we look forward to his input at this important time for Mach7. Wayne brings with him extensive experience in product development and driving sales growth in emerging and mature markets. Wayne also has a proven track record in mergers and acquisitions and has worked in both MNCs and fast growing technology companies like Mach7. We look forward to his contributions to the Board.”
“I also take this opportunity to thank Ken for his contribution to the Company. Ken was instrumental to the success of the Company’s recent merger and financings. Regrettably, he’s had to step down given his business commitments. On behalf of the Board I wish him well in his future endeavours.”
==> picture [610 x 123] intentionally omitted <==
ASX Announcement
15 June 2016
==> picture [610 x 89] intentionally omitted <==
An Appendix 3X (Initial Director's Interest Notice) in relation to Mr Spittle and an Appendix 3Z (Final Director’s Interest Notice) in relation to Mr Poutakidis will follow shortly.
About Mach7 Technologies:
Mach7 Technologies is a global provider of enterprise image management systems that allow healthcare enterprises to easily identify, connect, and share diagnostic images and patient care intelligence where and when needed. Mach7’s award-winning platform delivers image management including rapid record identification, integration, synchronisation and routing, advanced clinical viewing, and optimized vendor neutral archiving. Mach7 has locations in the U.S., Asia, Australia, Africa and the Middle East. For more information, visit www.mach7t.com.
Mach7’s wholly-owned subsidiary, 3D Medical Limited, provides medical specific 3D printing and is an exclusive distributor of various synergistic technologies including holographic projection. 3D Medical’s innovative products leverage data already captured by conventional imaging modalities and apply it in more meaningful ways to deliver improved economic and patient outcomes. For more information, visit www.3dmedical.com.au.
Contacts :
Albert Liong CEO +1 650 743 0167 (U.S.) [email protected]
Jenni Pilcher CEO Australia, CFO +61 3 9646 2222 (Australia) [email protected]
Julia Vaughn Investor Relations (U.S.) +1 802 768 0143 (U.S.) [email protected]
==> picture [610 x 123] intentionally omitted <==